Trials / Recruiting
RecruitingNCT05106387
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Noninterventional | No investigational treatment will be given in this noninterventional extension study |
Timeline
- Start date
- 2023-10-19
- Primary completion
- 2026-06-15
- Completion
- 2028-02-23
- First posted
- 2021-11-03
- Last updated
- 2026-04-17
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05106387. Inclusion in this directory is not an endorsement.